Early Corticosteroids Decrease Mortality in Critically Ill Patients with COVID-19: A Cohort Study

Pablo Monedero (pmonedero@unav.es)  Universidad de Navarra  https://orcid.org/0000-0002-1596-5644

Alfredo Gea  University of Navarra: Universidad de Navarra

Pedro Castro  Clinic Barcelona Hospital Universitari: Hospital Clinic de Barcelona

Angel M. Candela-Toha  Ramon y Cajal University Hospital: Hospital Universitario Ramon y Cajal

María L. Hernández-Sanz  Cruces University Hospital Servicio de Anaesthesiology Reanimation and Pain Therapy: Hospital Universitario de Cruces Servicio de Anestesiologia Reanimacion y Terapeutica del dolor

Egoitz Arruti  Ubikare Technology

Jesús Villar  HUGC Dr Negrin: Hospital Universitario de Gran Canaria Dr Negrin

Carlos Ferrando  Clinic Barcelona Hospital Universitari: Hospital Clinic de Barcelona

Research

Keywords: COVID-19, intensive care unit, corticosteroids, critically ill patient, cohort study, outcomes, ventilator-free days, mortality.

Posted Date: September 15th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-71610/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on January 4th, 2021. See the published version at https://doi.org/10.1186/s13054-020-03422-3.
Abstract

Background: Critically ill patients with coronavirus disease 19 (COVID-19) have a high fatality rate likely due to a dysregulated immune response. Corticosteroids could attenuate this inappropriate response, although there are still some concerns regarding its use, timing, and dose.

Methods: This is a nationwide, prospective, multicenter, observational, cohort study in critically ill adult patients with COVID-19 admitted into Intensive Care Units (ICU) in Spain from March 12th to June 29th, 2020. Using a multivariable Cox model with inverse probability weighting, we compared relevant outcomes between patients treated with early corticosteroids (before or within the first 48h of ICU admission) with those who did not receive early corticosteroids or any corticosteroids at all. Primary endpoint was ICU mortality. Secondary endpoints included 7-day mortality, ventilator-free days, and complications.

Results: A total of 691 patients out of 882 (78.3%) received corticosteroid during their hospital stay. Patients treated with early-corticosteroids (n=485) had a lower ICU mortality (30.3% vs 40.6%, HR 0.71, 95% CI 0.57-0.89) and higher number of ventilator-free days (mean difference 2.5 days, 95% CI 1.3-3.8) compared to non-early treated patients. There were no differences in 7-day mortality (HR 0.76, 95% CI 0.48-1.2), medical complications (OR 2.18, 95% CI 0.91-5.25) or secondary infections (OR 0.88, 95% CI 0.67-1.15) between both groups. Of note, early use of moderate-to-high doses was associated with better outcomes than low dose regimens.

Conclusion: Early use of corticosteroids in critically ill patients with COVID-19 is associated with lower mortality (10.3% absolute risk reduction) and shorter duration of mechanical ventilation.

Background

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first recognized in Wuhan, China, in December 2019 [1]. The anti-viral immune response is crucial to eliminate the invading virus. However, an inappropriate response may cause a systemic hyperinflammatory state, producing complications such as acute respiratory distress syndrome (ARDS) and multisystem organ failure [2]. Early treatment of this hyperinflammation may be important for reducing mortality in COVID-19 patients.

Corticosteroids are used to treat several hyperinflammatory syndromes [3]. Early after the outbreak, the World Health Organization (WHO) recommended against the routine use of systemic corticosteroids for treating COVID-19 patients, due to their known side effects and a potential slowing of viral clearance [1]. However, the RECOVERY trial has shown improved outcomes in COVID-19 patients treated with corticosteroids [4]. Consequently, the US National Institutes of Health (NIH) is recommending now the use of dexamethasone to treat COVID-19 patients requiring supplemental oxygen [5].
Spain is one of the European countries most affected by the COVID-19 pandemic with a broad experience in the use of corticosteroids in Intensive Care Units (ICU) for patients with ARDS [6]. In a large COVID-19 registry of patients admitted into a network of ICUs, we examined whether early use of corticosteroids decreases all-cause mortality and improves clinically relevant outcomes.

Methods

Study design

This is a multicentre, observational study with retrospective analysis of prospectively collected data in consecutive critically ill COVID-19 patients admitted from March 12th to June 29th, 2020 into a network of ICUs in 36 hospitals from Spain and Andorra. The study was approved by a referral Ethics Committee (Ethics Committee of Euskadi, Spain) and by all participating hospitals.

Data source and study population

Following a standardized protocol, site investigators collected data from electronic medical records. We recorded pre-admission and daily data from ICU admission to ICU discharge. Before data analysis, two independent investigators and a statistician screened the database for errors against standardized ranges and contacted site investigators with queries.

All consecutive COVID-19 patients admitted to participating ICUs, were considered for study entry if they had: age ≥18 years and confirmed SARS-CoV-2 infection from a respiratory tract sample using RT-PCR assay. Exclusion criteria were non-confirmed SARS-CoV-2 infection, patients with no data at baseline, patients with do-not-resuscitate orders, and patients who did not meet the outcomes of death or ICU discharge by June 29th, 2020.

Variables, Exposures, and Endpoints

We recorded data on demographics and comorbidities according to established definitions (See Additional File), laboratory findings, vital signs, severity scores at ICU admission, supportive therapies, and relevant outcomes reported by June 29th, 2020. We collected pre-ICU-admission and full data set on the first day of ICU (baseline), and the “worst” values during ICU stay (maximum or minimum, depending on the parameter).

For this study, we established a post-hoc cut-off at 48 hours after ICU admission, and classified patients in two groups: (i) patients receiving corticosteroids within the first 48 hours (early-treated group); (ii) patients receiving corticosteroids after 48 hours or never (non-early group). Other exploratory exposures included the administration of corticosteroids at any time during hospital stay (ever-treated group = early plus delayed use) and no administration at all (never-treated group). We also examined patients receiving low dose of corticosteroids (defined as methylprednisolone < 1 mg/kg/d or dexamethasone < 0.12
mg/kg/d or prednisone < 0.5 mg/kg/d) or receiving moderate-to-high doses (any dose higher than low dose).

The primary endpoint was ICU mortality. We excluded from the analysis patients who died or were discharged within the first 48 hours. Secondary endpoints were medical and infectious complications, ventilator-free days, ICU length of stay (LOS), and 7-day mortality.

**Statistical analysis**

We aimed to enrol as many patients as possible, with no pre-defined sample size.

We report the values of variables as percentages, mean and standard deviation (SD), or median and interquartile range (IQR), as appropriate. To compare variables among groups, we used Student t-test or Mann-Whitney test and one-way ANOVA or Kruskal-Wallis test for numerical variables, and Chi-squared test or Fisher exact test for categorical variables.

To assess the relationship between corticosteroids treatment and endpoints, time-to-event curves were plotted using the Kaplan-Meier method and analysed with Cox regression analysis. For the Kaplan-Meier curves, patients with complementary outcomes were right-censored at the longest recorded LOS. We used inverse probability of treatment weighting (IPW) for baseline differences between treatment groups. We fitted logistic models using the following baseline variables: age, gender, comorbidities (diabetes mellitus and arterial hypertension), APACHE II and SOFA scores, and PaO\(_2\)/FiO\(_2\) at admission. Weights were calculated following the methodology described elsewhere [7], and a pseudo-population (adjusted sample) was built subsequently. The 95% confidence intervals (CI) were the 2.5\(^{th}\) and 97.5\(^{th}\) percentiles of the distribution obtained from a nonparametric bootstrap with 1,000 samples. To test the robustness of results, we rerun the primary analysis under several assumptions and scenarios (See Additional File).

Missing data were not imputed. Analyses were performed in a complete case analysis basis. All tests were two-sided, and a p-value <0.05 was considered statistically significant. Analyses were performed using STATA version 16.

**Results**

From 1,102 consecutive patients with COVID-19, we analysed 882 patients (Fig. 1). Baseline characteristics are reported in Table 1. Acute hypoxemic respiratory failure was the main reason for ICU admission.
### Table 1
Baseline Characteristics of Patients Receiving or Not Receiving Early Corticosteroids (in the first 48 hours of ICU admission)

| Patients demographics and comorbidities | Whole cohort | Non-early | Early corticosteroids | p-value |
|-----------------------------------------|--------------|-----------|-----------------------|---------|
| **N (%)**                               | 882          | 397 (45.01%) | 485 (54.99%)         |         |
| **Age, years**                          | 62.3 (11.4)/877 | 61.6 (12.4)/394 | 62.9 (10.6)/483 | 0.17    |
| **Female (%)**                          | 291/880 (33.1%) | 138/395 (34.9%) | 153/485 (31.5%) | 0.31    |
| **Body mass index (kg/m$^2$)**          | 29.2 (5.37)/550 | 29.1 (5.40)/258 | 29.2 (5.35)/292 | 0.93    |
| **Arterial Hypertension**               | 420/882 (47.62%) | 180/397 (45.34%) | 240/485 (49.48%) | 0.22    |
| **Diabetes Mellitus**                   | 201/882 (22.79%) | 90/397 (22.67%) | 111/485 (22.89%) | 1.00    |
| **Chronic heart failure**               | 13/882 (1.47%) | 6/397 (1.51%) | 7/485 (1.44%) | 1.00    |
| **Chronic renal failure**               | 52/882 (5.90%) | 24/397 (6.05%) | 28/485 (5.77%) | 0.88    |
| **Asthma**                              | 24/882 (2.72%) | 8/397 (2.02%) | 16/485 (3.30%) | 0.30    |
| **COPD**                                | 40/882 (4.54%) | 16/397 (4.03%) | 24/485 (4.95%) | 0.62    |
| **Obese**                               | 299/792 (37.75%) | 141/357 (39.50%) | 158/435 (36.32%) | 0.37    |
| **Dyslipidemia**                        | 132/882 (14.97%) | 56/397 (14.11%) | 76/485 (15.67%) | 0.56    |
| **Cancer**                              | 27/882 (3.06%) | 19/397 (4.79%) | 8/485 (1.65%) | 0.01    |

| Laboratory findings                     | Whole cohort | Non-early | Early corticosteroids | p-value |
|-----------------------------------------|--------------|-----------|-----------------------|---------|
| **Hematocrit (%)**                     | 39.2 (5.7)/602 | 39.0 (5.9)/289 | 39.4 (5.6)/313 | 0.35    |
| **Platelets, 1000/mm$^3$**              | 236 (108)/672 | 227 (108)/305 | 243 (109)/367 | 0.05    |
| **Leukocytes, 10$^3$/µL**              | 9.07 (5.81)/663 | 8.62 (5.37)/303 | 9.45 (6.14)/360 | 0.03    |
| **Lymphocytes, µL**                     | 0.82 (0.72)/658 | 0.79 (0.47)/297 | 0.84 (0.87)/361 | 0.51    |
| **CRP, mg/dL**                          | 74.5 (98.9)/623 | 81.5 (105.4)/274 | 69.0 (93.3)/349 | 0.02    |
| **Lactate, mmol/L**                     | 0.43 (0.94)/475 | 0.43 (1.01)/230 | 0.44 (0.88)/245 | 0.13    |

COPD: Chronic Obstructive Pulmonary Disease; CRP: C-Reactive Protein; LDH: Lactate dehydrogenase; AST: Aspartate Aminotransferase; NTProBNP: N-terminal pro-brain natriuretic peptide; APACHE: Acute Physiology and Chronic Health Evaluation; CURB65: Confusion, uremia, elevated respiratory rate, hypotension, and aged 65 years or older; SOFA: Sequential Organ Failure Assessment
|                         | Whole cohort | Non-early | Early corticosteroids | p-value |
|-------------------------|--------------|-----------|-----------------------|---------|
| Ferritin, ng/mL         | 1665 (1658)/285 | 1561 (1641)/106 | 1726 (1669)/179       | 0.26    |
| D- Dimer, ng/mL         | 2026 (2339)/522 | 1825 (2094)/230 | 2185 (2507)/292       | 0.17    |
| CRP/lymphocyte ratio    | 131 (234)/617 | 156 (295)/273 | 111 (169)/344         | 0.03    |
| IL-6, pg/mL             | 253 (486)/87  | 163 (290)/25  | 289 (544)/62          | 0.47    |
| LDH, U/L                | 484 (240)/595 | 485 (267)/265 | 484 (215)/330         | 0.27    |
| Procalcitonin, ng/mL    | 1.36 (5.11)/454 | 1.64 (6.30)/194 | 1.15 (3.99)/260       | 0.27    |
| Bilirubin, mg/dL        | 0.82 (1.16)/567 | 0.88 (1.62)/245 | 0.76 (0.61)/322       | 0.73    |
| AST, U/L                | 58.3 (86.6)/650 | 59.7 (111.0)/291 | 57.2 (60.1)/359       | 0.40    |
| Creatinine, mg/dL       | 1.05 (0.68)/658 | 1.07 (0.71)/297 | 1.03 (0.66)/361       | 0.70    |
| Urea, mg/dL             | 46.5 (28.0)/462 | 46.3 (28.7)/197 | 46.6 (27.5)/265       | 0.75    |
| NTProBNP, pg/mL         | 1880 (5166)/96 | 2068 (6380)/46 | 1707 (3780)/50        | 0.09    |
| Temperature, °C         | 36.9 (1.1)/654 | 37.1 (1.1)/309 | 36.7 (1.0)/345        | < 0.001 |
| Mean arterial pressure, mmHg | 86.7 (15.3)/644 | 86.6 (14.7)/303 | 86.8 (15.8)/341       | 0.78    |
| Heart rate, bpm         | 85.2 (18.8)/658 | 86.4 (18.6)/312 | 84.1 (18.9)/346       | 0.19    |
| SpO₂, %                 | 88.1 (9.2)/641 | 87.7 (10.5)/299 | 88.5 (7.8)/342        | 0.56    |
| Respiratory rate, bpm   | 25.7 (7.3)/604 | 26.7 (8.0)/283 | 24.9 (6.6)/321        | 0.005   |
| PaO₂/FiO₂               | 150 (77)/559   | 149 (77)/254  | 151 (78)/305          | 0.76    |
| Apache II               | 13.51 (6.35)/600 | 13.14 (5.87)/252 | 13.77 (6.67)/348      | 0.54    |
| CURB65                  | 1.86 (1.22)/288 | 1.80 (1.20)/138 | 1.93 (1.23)/150       | 0.33    |
| SOFA                    | 5.64 (2.94)/474 | 5.70 (2.88)/208 | 5.58 (2.99)/266       | 0.42    |

COPD: Chronic Obstructive Pulmonary Disease; CRP: C-Reactive Protein; LDH: Lactate dehydrogenase; AST: Aspartate Aminotransferase; NTProBNP: N-terminal pro-brain natriuretic peptide; APACHE: Acute Physiology and Chronic Health Evaluation; CURB65: Confusion, uremia, elevated respiratory rate, hypotension, and aged 65 years or older; SOFA: Sequential Organ Failure Assessment
Four-hundred and eighty-five patients (55.0%) were treated with early corticosteroids (See Supplementary Table S1). Corticosteroid exposure did not differ according to age, sex, body-mass index, severity scores, and main comorbidities (Table 1). During ICU stay, corticosteroid early-treated patients developed less organ dysfunction, had less requirement for renal replacement therapy (RRT), and less systemic inflammation than non-early treated patients (Table 2).
|                       | Whole cohort | Non-early | Early corticosteroids | p-value |
|-----------------------|--------------|-----------|-----------------------|---------|
| n (%)                 | 882          | 397 (45.01%) | 485 (54.99%)          |         |
| Mechanical ventilation, n (%) | 722/882 (81.86%) | 327/397 (82.37%) | 395/485 (81.44%) | 0.79    |
| Vasopressor use, n (%) | 639/882 (72.45%) | 296/397 (74.56%) | 343/485 (70.72%) | 0.22    |
| Renal replacement therapy, n (%) | 96/867 (11.07%) | 56/388 (14.43%) | 40/479 (8.35%) | 0.006   |
| SOFA maximum          | 8.56 (3.66)/729 | 9.07 (3.88)/303 | 8.20 (3.46)/426 | 0.004   |

**Vital Signs**

|                        | Whole cohort | Non-early | Early corticosteroids | p-value |
|------------------------|--------------|-----------|-----------------------|---------|
| Temperature maximum, ºC | 37.87 (1.04)/869 | 38.05 (1.01)/388 | 37.73 (1.04)/481 | < 0.001 |
| Mean arterial pressure minimum, mmHg | 68.77 (12.98)/868 | 68.42 (13.00)/388 | 69.06 (12.98)/480 | 0.22    |
| Heart rate maximum, bpm  | 105.65 (20.91)/868 | 106.87 (20.93)/388 | 104.65 (20.87)/480 | 0.12    |
| SpO₂, minimum, %       | 78.64 (16.20)/869 | 77.67 (17.46)/389 | 79.42 (15.09)/480 | 0.37    |
| Respiratory rate, maximum, bpm | 30.46 (7.04)/859 | 31.34 (7.42)/382 | 29.76 (6.64)/477 | 0.002   |
| Respiratory rate, minimum, bpm | 17.19 (4.44)/859 | 17.28 (4.51)/382 | 17.12 (4.38)/477 | 0.55    |

**Arterial blood gas**

|                        | Whole cohort | Non-early | Early corticosteroids | p-value |
|------------------------|--------------|-----------|-----------------------|---------|
| PaO₂/FiO₂ minimum      | 98.3 (47.9)/833 | 100.4 (52.9)/367 | 96.6 (43.5)/466 | 0.40    |
| PaCO₂ maximum, mmHg    | 61.8 (19.3)/855 | 65.3 (20.2)/382 | 59.0 (18.0)/473 | < 0.001 |

**Laboratory findings**

|                        | Whole cohort | Non-early | Early corticosteroids | p-value |
|------------------------|--------------|-----------|-----------------------|---------|
| Ferritin maximum, ng/mL | 2305 (2257)/667 | 2293 (2269)/278 | 2315 (2252)/389 | 0.80    |
| D-Dimer maximum, ng/mL  | 5124 (2983)/809 | 5058 (2954)/357 | 5176 (3009)/452 | 0.61    |

SOFA: Sequential Organ Failure Assessment; CRP: C-Reactive Protein; LDH: Lactate dehydrogenase; AST: Aspartate Aminotransferase; NTProBNP: N-terminal pro-brain natriuretic peptide
|                           | Whole cohort | Non-early | Early corticosteroids | p-value |
|---------------------------|-------------|-----------|-----------------------|---------|
| CRP maximum, mg/dL        | 121 (138)/845 | 134 (148)/373 | 111 (128)/472          | 0.003   |
| Lymphocytes minimum, mL   | 0.45 (0.34)/848 | 0.49 (0.37)/377 | 0.42 (0.31)/471        | 0.002   |
| CRP/lymphocyte ratio max. | 273 (447)/843 | 308 (509)/372 | 246 (390)/471          | 0.11    |
| IL-6 maximum, pg/mL       | 957 (1787)/314 | 1010 (1756)/96 | 933 (1804)/218         | 0.39    |
| LDH maximum, U/L          | 648 (382)/828  | 633 (366)/361  | 660 (394)/467          | 0.16    |
| Leukocytes maximum, 10^3/mL | 15.46 (10.00)/843 | 14.58 (9.30)/376 | 16.17 (10.49)/467    | 0.01    |
| Procalcitonin maximum, ng/mL | 4.13 (9.92)/756 | 5.49 (12.49)/322 | 3.11 (7.32)/434      | < 0.001 |
| Platelets maximum, 1000/mm³ | 387 (153)/852  | 399 (158)/379  | 377 (150)/473          | 0.01    |
| Bilirubin, maximum, mg/dL | 2.34 (3.66)/803 | 2.42 (3.93)/342 | 2.28 (3.45)/461       | 0.76    |
| AST maximum, U/L          | 198 (372)/845  | 196 (402)/375  | 199 (346)/470          | 0.06    |
| Creatinine maximum, mg/dL | 1.84 (1.69)/851 | 2.00 (1.84)/378 | 1.71 (1.55)/473       | 0.14    |
| Urea maximum, mg/dL       | 115 (161)/764  | 127 (228)/341  | 106 (69)/423           | 0.78    |
| NTProBNP, maximum pg/mL   | 1996 (4816)/261 | 2430 (4970)/109 | 1685 (4694)/152       | 0.01    |
| Hematocrit minimum, %     | 38.19 (5.98)/834 | 37.42 (6.07)/370 | 38.80 (5.85)/464      | 0.001   |
| Lactate maximum, mmol/L   | 0.37 (0.81)/692  | 0.38 (0.90)/300  | 0.36 (0.74)/392       | 0.28    |

SOFA: Sequential Organ Failure Assessment; CRP: C-Reactive Protein; LDH: Lactate dehydrogenase; AST: Aspartate Aminotransferase; NTProBNP: N-terminal pro-brain natriuretic peptide

**Primary Outcome**

Overall ICU mortality was 34.9% (n = 308), significantly lower in the early corticosteroids group (30.3%) than in non-early-treated group (40.6%) (HR 0.71, 95% CI 0.57–0.89) (Table 3, Fig. 2). A sensitivity analysis showed less mortality reduction with corticosteroids in women, patients < 60-year-old, with hypertension, cancer, or type 2 diabetes, CRP < 10 mg/dL, D-Dimer > 1500 ng/mL, ICU admission > 8 days after the onset of symptoms, corticosteroids within 7 days of symptom onset, PaFiO₂ > 200, or APACHE score > 14 at ICU admission (Table S2). The reduction in mortality with corticosteroids was independent of treatment with tocilizumab, initiation of steroids before ICU admission, need of invasive mechanical ventilation (MV), lymphocytes count, duration of corticosteroids treatment, or the admitting hospital (Table S2). This reduction in mortality was also observed when including the 149 patients not discharged from ICU or when including “missing” as a category in the IPW cohort.
Table 3
Outcomes according to early corticosteroids use in the first 48 h of ICU admission. IPW subcohort, n = 455

| Outcome                                      | Whole cohort | Non-early   | Early corticosteroids | p-value |
|----------------------------------------------|--------------|-------------|------------------------|---------|
| n (%)                                        | 882          | 397 (45.01%)| 485 (54.99%)           |         |
| ICU mortality, cases/person-days             | 308 (34.9%)/57,589 | 161 (40.6%)/24,414 | 147 (30.3%)/33,148 |         |
| ICU mortality (hazard ratio)                 | 1 (Ref.)     | 0.71 (0.57, 0.89) |   | 0.003 |
| ICU mortality (hazard ratio) IP-weighted*    | 1 (Ref.)     | 0.56 (0.39, 0.79) |   | 0.002 |
| 7-day mortality, cases/person-days           | 72 (8.2%)/4230 | 37 (9.3%)/1874 | 35 (7.2%)/2356 |         |
| 7-day mortality (hazard ratio)               | 1 (Ref.)     | 0.76 (0.48, 1.20) |   | 0.23  |
| 7-day mortality (hazard ratio) IP-weighted*  | 1 (Ref.)     | 0.54 (0.20, 1.25) |   | 0.11  |
| ICU length of stay, days                     | 17.8 (14.2)  | 19.7 (15.9)  | 16.4 (12.5)            | < 0.001|
| ICU length of stay (mean difference)         | 0 (Ref.)     | -3.3 (-5.2, -1.4) |   | 0.001 |
| ICU length of stay (mean difference) IP-weighted* | 0 (Ref.)  | -4.6 (-8.4, -2.2) |   | 0.002 |
| ICU length of stay among survivors, days     | 18.1 (14.7)  | 20.2 (16.6)  | 16.6 (13.1)            | 0.004  |
| ICU length of stay among survivors (mean difference) | 0 (Ref.) | -3.6 (-6.1, -1.2) |   | 0.01  |
| ICU length of stay among survivors (mean difference) IP-weighted* | 0 (Ref.) | -4.3 (-9.5, -2.1) |   | 0.01  |
| Ventilatory-free days                        | 8.4 (9.4)    | 7.0 (9.1)    | 9.6 (9.5)              | < 0.001|
| Ventilatory-free days (mean difference)      | 0 (Ref.)     | 2.5 (1.3, 3.8) |   | < 0.001|
| Ventilatory-free days (mean difference) IP-weighted* | 0 (Ref.)  | 3.1 (1.9, 5.2) |   | < 0.001|
| Medical complications, n (%)                 | 860 (97.5%)  | 383/397 (96.5%) | 477/485 (98.4%) |         |
| Medical complications (odds ratio)           | 1 (Ref.)     | 2.18 (0.91, 5.25) |   | 0.08  |
|                           | Whole cohort | Non-early | Early corticosteroids | p-value |
|---------------------------|--------------|-----------|-----------------------|---------|
| Medical complications (odds ratio) IP-weighted* | 1 (Ref.) | 2.63 (0.45, 10.61) | 0.12 |
| Infectious complications, n (%) | 509 (57.7%) | 236/397 (59.5%) | 273/485 (56.3%) |
| Infectious complications (odds ratio) | 1 (Ref.) | 0.88 (0.67, 1.15) | 0.34 |
| Infectious complications (odds ratio) IP-weighted* | 1 (Ref.) | 0.76 (0.56, 1.25) | 0.15 |

ICU mortality was lower when using moderate-to-high doses of corticosteroids (26.9% vs. 32.8%, (HR 0.58, 95% CI 0.45–0.75) (Table S3-S4, Figure S1).

**Secondary outcomes**

Patients treated with early corticosteroids had shorter ICU LOS (Table 3), lower rate of acute renal failure (HR 0.64; 95%CI, 0.48–0.84), higher rates of hyperglycaemia, and higher levels of aspartate transaminases. There were no differences in the rate of secondary infections between groups.

Regarding corticosteroids **doses**, early use of moderate-to-high doses, compared with low doses, was associated with a shorter ICU LOS, lower organ dysfunction, less requirement of MV or RRT, and no increase in medical or infectious complications (Table S3-S4).

Patients who **never** received corticosteroids were a less severe population: younger, with fewer signs of organ damage and inflammation, and lower requirement for MV. Nonetheless, compared with early-treated patients, they had higher ICU mortality (36.6% vs. 30.3%, HR 0.55, 95% CI 0.35–0.93) (Tables S5-6, Figure S2). In contrast, compared with ever-treated patients, they had no difference in ICU survival, but lower LOS, less requirement for mechanical ventilation and vasopressors, better disease progression, and a lower number of infectious complications (Tables S7-S8, Figure S3).

**Discussion**

The major findings of our study are that early use of corticosteroids in critically ill patients with COVID-19 was associated with: (i) lower ICU mortality when compared to delayed or no use of corticosteroids; (ii) shorter ICU LOS; (iii) decreased organ dysfunction, and (iv) fewer days on MV, with no increase in medical or infectious complications. These findings remained statistically significant after adjusting for age, gender, comorbidities, severity, and PaO$_2$/FiO$_2$ at admission.

To study the influence of corticosteroids on mortality in our cohort we set a cut-off point of 48 hours after admission to ICU. We consider this period long enough for an experienced clinician to assess patients’ response to initial support and therapy and modify them accordingly. We have tried to solve the question
placed by many clinicians: shall I start corticosteroids in this patient? Like an intention-to-treat analysis, patients receiving corticosteroids after 48 h of ICU admission were not excluded because the decision to start therapy in this group was probably guided by other uncontrolled factors.

Two recent publications support the early and selective use of corticosteroids in symptomatic patients infected with SARS-COV-2. The RECOVERY trial found a reduction in 28-day mortality in hospitalized COVID-19 patients treated with dexamethasone if they required oxygen or MV [4]. The study by Fadel et al. [8] found that an early short course of methylprednisolone in moderate-to-severe COVID-19 reduced escalation of ICU care, need for MV, and hospital mortality. Our study reinforces those results, especially in critically ill COVID-19 patients. Of note, these findings are in contrast with previous reports on corticosteroid therapy in past outbreaks of other coronaviruses (SARS-CoV, MERS-CoV), or other viral pneumonia (Influenza, Respiratory Syncytial Virus) [9–13].

Our sensitivity analysis showed that early use of corticosteroids was not as effective in women, in those with lower risk of death—younger patients with good oxygenation and less inflammation—and neither in those with greater risk or severity—cancer, diabetics, D-Dimer > 1500 ng/mL, APACHE score > 14—. These findings suggest that patient characteristics should be assessed before prescribing corticosteroids.

In clinical practice, corticosteroids are used in most critically ill patients [13]. The extensive use of corticosteroids in our cohort reflects the severity of our patients (almost 60% directly admitted to ICU upon arrival to the hospital, 81.9% with invasive mechanical ventilation in the first 48 hours after ICU admission, and with a mean PaO2/FiO2 = 150). Since observational studies are prone to selection bias, we used inverse probability of treatment weighting to tackle this problem. Corticosteroid therapy is further entangled by other factors that merit discussion, including timing, type of corticosteroids, duration of treatment, and dosing.

Our average time to corticosteroids administration was 12 days after symptom onset (Table S1), like the 13 days in the RECOVERY study for mechanically ventilated patients [4]. The decision to initiate corticosteroid therapy in our patients was guided when signs of hyperinflammation and severity of respiratory failure were evident. The delay or non-use of corticosteroids in 45% of our patients may reflect the controversy on their benefit/harm profile, WHO recommendations [1], or significant changes in clinical evolution. Ideally, we should start corticosteroid therapy in the initial phases of the hyperinflammatory state. Early use in the absence of hyperinflammation could be harmful, especially in the initial stage of viral replication [4, 14–15]. Similar to the RECOVERY trial, we have also found that corticosteroids were not associated with a reduction in mortality among those patients with symptoms duration under 7 days. One possible explanation is that corticosteroids may slow viral clearance in such an early phase. However, studies on viral clearance have yielded contradictory results [16–19]. Unfortunately, we did not collect time to viral clearance.

Interestingly, patients who never received corticosteroids had higher mortality than early-treated patients, a difference that was not observed when we compare them with ever-treated patients, that includes early plus delayed treatment. Delayed corticosteroids, when advanced organ damage already exists, might be
ineffective and even detrimental, as previously described in ARDS [20], with increased infectious complications and mortality, counteracting the positive effect of early treatment. The absence of benefit with too early use of corticosteroids (within 7 days of symptom onset), together with the beneficial effect of early use, and the worst results with delayed use, reveals a U-shaped time-outcome relationship. Although we do not know the optimal time to start corticosteroids, probably patients with elevated inflammatory markers after seven days of symptoms, requiring oxygen or ventilatory support may benefit the most, whereas those who have not received corticosteroids in early phases, probably will not benefit afterwards.

To the best of our knowledge, recommendations about dose and duration of corticosteroid treatment are empiric. With large doses and long treatments, the potential for adverse effects increases, and the possible benefit is lost [21]. The Italian National Institute for Infectious Diseases recommends a 10-day regimen: 5-days full dose of methylprednisolone 1 mg/Kg daily or dexamethasone 20 mg daily, and five days for tapering [22]. In general, most regimens for acute hyperinflammatory states recommend treatments shorter than two weeks [22, 23]. Most common dose regimens range between 0.5-2 mg/kg/day of methylprednisolone, equivalent to 0.1–0.4 mg/kg/day of dexamethasone, defined in our study as moderate-to-high doses. The cut-off points were defined before the publication of the RECOVERY trial that used a fixed dexamethasone dose (6 mg) lower than described in the literature for ARDS [6]. We observed a greater mortality reduction with a moderate-to-high dose regimen, similar to other studies [6, 24]. Although our classification is artificial, it favours a higher dose of corticosteroids. As a result of RECOVERY trial, the NIH recommend a low fixed dose of daily dexamethasone [4–5], but future comparative studies with higher doses are warranted [6]. Also, the beneficial effects of early corticosteroids in our patients expand beyond an absolute reduction in all-cause mortality, including a shorter ICU LOS, less organ dysfunction, and an increase in ventilator-free days.

This study has several strengths. First, this multicentre nationwide prospective data collection with over 1,000 patients from 36 ICUs provides a very detailed description of all gathered data from ICU admission to death or ICU discharge. Second, to the best of our knowledge, this is the first observational study that prospectively explores the association between different doses and timings of corticosteroid therapy in COVID-19 patients and ICU mortality. Third, we have used IPW to control for confounding with pre-specified demographic, comorbidities, and severity parameters. However, we acknowledge some limitations of our study. First, the observational nature of our study design. Although we adjusted for likely confounders, some unmeasured confounding is still possible. Second, we cannot exclude missing data for some variables and potential for inaccuracies in the electronic health records due to the burden of care experienced by participating clinicians during the pandemic. However, due to the nature of our registry, we consider that selection bias was not favoured, and our analyses are valid. Third, although moderate-to-high doses of dexamethasone were most effective, no firm conclusions can be drawn on the drug or the dose, as our hypothesis and the definition of variables in the protocol preclude to do so, and doses predefined as low are not completely equivalent and could be controversial. Finally, at the time of the analysis, 149 (13.5%) patients did not have a definitive outcome regarding status at ICU discharge and were not included in the main analysis, although included in the sensitivity analyses.
Conclusions

In conclusion, in critically ill COVID-19 patients with acute respiratory failure, the use of corticosteroids within the first 48 h of ICU admission was associated with a marked reduction in ICU mortality and ICU LOS. We also found a clear relationship between exposure and a beneficial effect on organ dysfunction. Further research is needed to characterize the optimal drug, onset, dose, and duration of corticosteroids therapy in this patient population.

Abbreviations

**COVID-19**: Coronavirus disease 2019

**SARS-CoV-2**: severe acute respiratory syndrome coronavirus 2

**ARDS**: acute respiratory distress syndrome

**WHO**: World Health Organization

**NIH**: US National Institutes of Health

**ICU**: Intensive Care Unit

**SD**: standard deviation

**IQR**: interquartile range

**LOS**: length of stay

**IPW**: inverse probability of treatment weighting

**APACHE**: Acute Physiology and Chronic Health disease Classification System

**SOFA**: Sequential Organ Failure Assessment

**CI**: confidence interval

**RRT**: renal replacement therapy

**HR**: Hazard ratio

Declarations

**Ethics approval**: Approval was obtained from the referral Ethics Committee of Euskadi, Spain (by Nagore García Goitiandia. Secretaria del CEIm de Euskadi. Código interno: P12020069. Versión del Protocolo:
The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

**Consent to participate:** The need for written informed consent from participants was considered by each participating centre

**Consent for publication:** Not applicable

**Availability of data and materials:** After publication, data will be made available to other investigators on reasonable requests to the corresponding author. A proposal with a detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Additional materials might also be required during the process of evaluation. Deidentified participant data will be provided after approval from the corresponding author.

**Competing interests:** We declare no competing interests.

**Funding:** None

**Authors' contributions:** PM, PC, ACT, MH, CF, and the COVID-19 Spanish ICU Network collected the clinical data. AG, EA, and CF performed the initial data analysis and interpretation. PM and PC summarised all data. ACT, AG, CF, PM, and JV drafted the manuscript. JV, MH, and PC contributed to data interpretation and revised the final manuscript. All authors contributed to critical revision of the manuscript for intellectual content, and all are responsible for the content of this paper.

**Acknowledgments:** We thank all patients and their families involved in the study.

We would like the names of the individual members of the COVID-19 Spanish ICU Network Group to be searchable through their individual PubMed records.

Investigators of the COVID-19 Spanish ICU Network are:

**Hospital Clínic de Barcelona, Department of Anesthesiology and Critical Care:** Marina Vendrell, Gerard Sánchez-Etayo, Amalia Alcón, Isabel Belda, Mercé Agustí, Albert Carramiñana, Isabel Gracia, Miriam Panzeri, Irene León, Jaume Balust, Ricard Navarro, María José Argúís, María José Carretero, Cristina Ibáñez, Juan Perdomo, Antonio López, Manuel López-Baamonde, Tomás Cuñat, Marta Ubré, Antonio Ojeda, Andrea Calvo, Eva Rivas, Paola Hurtado, Roger Pujol, Nuria Martín, Javier Tercero, Pepe Sanahuja, Marta Magaldi, Miquel Coca, Elena del Rio, Julia Martínez-Ocon, Paula Masgoret, Angel Caballero, Raquel Risco, Lidia Gómez, Nicolás de Riva, Ana Ruiz, Beatriz, Tena, Sebastián Jaramillo, José María Balibrea, Francisco Borja de Lacy, Ana Otero, Ainätze Ibarzabal, Raquel Bravo, Anna Carreras, Daniel Martín-Barreda, Alfonso Jesús Alias, Mariano Balaguer, Jorge Aliaga, Alex Almuedo, Joan Ramón Alonso, Rut Andrea, Gerard Sergi Angelèes, Marilyn Arias, Fátima Aziz, Joan Ramon Badia, Enric Barbeta, Toni Torres, Guillem Batiste, Pau Benet, Xavi Borrat, María Borrell, Ernest Bragulat, Inmaculada Carmona, Manuel Castellà, Pedro Castro, Joan Ceravalls, Oscar Comino, Claudia Cucciniello, Clàudia De Deray, Oriol De Diego, Paula
De la Matta, Marta Farrero, Javier Fernández, Sara Fernández, Anna Fernández, Miquel Ferrer, Ana Fervienza, María Tallo Forga, Daniel Forné, Clàudia Galán, Andrea Gómez, Eduard Guasch, María Hernández-Tejero, Adriana Jacas, Beltrán Jiménez, Pere Leyes, Teresa López, José Antonio Martínez, Graciela Martínez-Pallí, Jordi Mercadal, Guido Muñoz, José Muñoz, Ricard Navarro, Josep María Nicolás, José Tomás Ortiz, Anna Peiró, Manuel Pérez, Esteban Poch, Margarida Pujol, Eduard Quintana, Bartomeu Ramis, Enric Reverter, Irene Rovira, Pablo Ruiz, Elena Sandoval, Stefan Schneider, Oriol Sibila, Carla Solé, Alex Soriano, Dolors Soy, M. Suárez, Adrián Téllez, Néstor David Toapanta, Antoni Torres, Xavier Urra.

Hospital Universitario Río Horta: César Aldecoa, Oscar Bordell, Silvia Martín, Judith Andrés. **Hospital Universitario Cruces:** Alberto Martínez Ruiz, Gonzalo Tamayo Medel, Iñaki Bilbao Villasante, Fernando Iturri Clavero, Covadonga Peralta Álvarez, Julia T. Herrera Díez, Andrea García Trancho, Iñaki Sainz Mandiola, Carmen Ruano Suarez, Angela Ruiz Bocos, Eneritz Urrutia Izagirre, Pablo Ortiz de Urbina Fernández, Naïara Apodaka López, Leire Prieto Molano, Eunate Ganuza Martínez, Iratxe Vallinas Hidalgo, Karme de Orte Sancho, Celia González Paniagua, Gemma Ortiz Labrador, Mireia Pérez Larranaga, Marta López Miguezuez, Estíbaliz Bárcena Andrés, Erik Urutxurtu Laureano, Maria Jesús Maroño Boedo, Blanca Escontrela Rodríguez, Aitziber Ereñozaga Camiruaga, Deiene Lasuen Aguirre, Ainhoa Zabal Maeztu, Ane Guereca Gala, Ikert Castelo Korro, Andrés Álvarez Campo, Alejandro Carcelen Viana, Alejandro Alberdi Enríquez, Xabier Ormazábal Rementeria, Alberto Sánchez Campos, Rosa Gutiérrez Rico, Pablo Barbier Damborenea, Marta Guerenabarrena Momeñe, Borja Cuesta Ruiz, Alejandro López Rico, Ana Rojo Polo, Covadonga García Grijelmo, Mikel Celorio Reta, Eneko Martín Arroyo, Leire Artaza Aparicio, Iñaki Iturarte Aspiazu, Ane Igeregi Basabe, Ixoxo Merino Julian, Isabel Diaz Rico, Maria Paz Martínez. **Hospital del Mar:** Ramón Adalia, Luigi Zattera, Irina Adalid Hernández, Leire Larranaga Altuna, Aina Serralonga Castells, Adriana Vilchez García, María Núñez, Lorena Román. **Hospital General Universitario de Ciudad Real:** Francisco Javier Redondo Calvo, Rubén Villazala González, Víctor Baladron González, Patricio Faba, Omar Montenegro, Natalia Bejarano Ramírez. **Complejo Asistencial Universitario León:** Sergio Marcos Contreras, Alejandro García Rodríguez, Saleta Rey Vázquez, Cristina García Pérez, Eva Higuera Miguezuez, Irene Pérez Blanco, David García Rivera. **Hospital Urduliz:** Ane Martín de la Fuente, Marta Pardo, Vanessa Rodríguez, Unai Bengoetxea. **Hospital Universitario de la Princesa:** Fernando Ramasco, Sheila Olga Santidrián Bernal, Alvar Santa Cruz Hernando, Antonio Planas Roca, Carlos Figueroa Yusta, Esther García Villabona, Carmen Vallejo Lantero, Eva Patiño Rodríguez, Alvaro Esquivel Toledo, David Arribas Méndez, Mar Orts Rodriguez, Rosa Méndez Hernández, Jesús Nieves Alonso, Inés Imaz Artazcoz, Sonia Expósito Carazo, Carlos Román Guerrero, Elena Rojo Rodríguez, Ricardo Moreno González, Julia Hernando Santos, Jara Torrente Pérez, Esperanza Mata Mena, Manuel José Muñoz Martínez, Enrique Alday Muñoz, Patricia Martin Serrano, Laura Cotter Muñoz, Amadea Mjertan, Diego Gutierrez Martínez, Carmen Rodríguez García, Olaya Alonso Viejo, Juan Álvarez Pereira, Ana Carmona Bonet, Diana Parrado López, Eva de Dios Tomas, Rafael Martín Celemín, María Luisa Meilan Paz, Luis Quecedo Gutiérrez, Noemí Díaz Velasco, Gabriel Martin Hernández, Francisco García del Corral, Gloria Hernandez Arias, David Rodriguez Cuesta, Ana Gómez Rice, Encarna Mateos Sevillano, Natalia Olmos Molpeceres.

**Hospital Povisa:** Beatriz Domínguez, Ana Vázquez Lima. **Hospital Ramón y Cajal:** Ángel Candela, Ismael A Acevedo Bambaren, María Isabel Albala Blanco, Paloma Alonso Montoír, Fernando Álvarez Utrera, Juan Avellanosa Esteruelas, Amal Azzam López, Alberto José Balvis Balvis, Tommaso Bardi, María
Beltrán Martín, Jacobo Benatar Haserfaty, Alberto Berruezo Camacho, Laura Betolaza Weimer, María del Mar Carbonell Soto, Cristina Carrasco Seral, Cristina Cerro Zaballos, Elizabeth Claros Llamas, Pilar Coleta Orduna, Ingrid P. Cortes Forero, Pascual Agustín Crespo Aliseda, María Angélica de Pablo Pajares, Yolanda Díez Remesal, Trinidad Dorado Díaz, Noemí Echevarría Blasco, María Elena Elías Martín, Javier Felices Triviño, Natalia Fernández López, Cristina Fernández Martín, Natalia Ferreiro Pozuelo, Luis Gajate Martín, Clara Gallego Santos, Diego Gil Mayo, María Gómez Rojo, Claudia González Cibrián, Elena Herrera López, Borja Hinojal Olmedillo, Berta Iglesias Gallego, Sassan Khonsari, María Nuria Mane Ruiz, María Manzanero Arroyo, Ana María Mariscal Ortega, Sara Martín Burcio, María del Carmen Martín González, Ascensión Martín Grande, Jose Juan Martín López, Cecilia Martín Rabes, Marcos Martínez Borja, Nilda Martínez Castro, Adolfo Martínez Pérez, Snejana Matcan, Cristina Medrano Viñas, Lisset Miguel Herrera, Adrián Mira Betancur, María Montiel Carbajo, Javier Moya Moradas, Lorena Muñoz Pérez, Mónica Nuñez Murias, Eva Ordiales González, Óscar Ordoñez Recio, Miguel Ángel Palomero Rodriguez, Diego Parise Roux, Lucía Pereira Torres, David Pestaña Lagunas, Juana María Pinto Corraliza, Marian Prieto Rodrigo, Inmaculada Rodríguez Díez-Regaño, David Rodríguez Esteban, Víctor Rojas Pernia, Álvaro Ruigómez Saiz, Bárbara Saavedra Villarino, Noemí Samaranch Palero, Gloria Santos Pérez, Jaume Serna Pérez, Ana Belén Serrano Romero, Jesús Tercero López, Carlos Tiscar García, Marta de la Torre Constrourca, Eva María Ureta Mesa, Eva Velasco Olarte, Judith Villahoz Martínez, Raúl Villalaba Palacios, Gema Villanueva García, Cristina Vogel de Medeiros. **Hospital Universitario Severo Ochoa:** Soraya Gholamian Ovejero, Marta Vicente Orgaz, Patricia Lloreda Herradon, Cristina Crespo Gómez. **Hospital Universitario de Gran Canaria Dr. Negrín:** Tatiana Sarmiento-Trujillo. **Hospital de Terrassa:** Noemí García Medina, María Martínez García, Carles Espinós Ramírez, Nabil Mouhaffel Rivero, Jose Antonio Bernia Gil. **Hospital Central de la Cruz Roja San José y Santa Adela:** Sonsoles Martín. **Hospital de la Santa Creu i Sant Pau:** María Victoria Moral, Josefina Galán, Pilar Paniagua, Sergio Pérez, Albert Bainac, Ana Arias, Elsa Ramil, Jorge Escudero. **Clínica Universidad de Navarra:** Departamento de Anestesia y Cuidados Intensivos: Pablo Monedero, Carmen Cara, Andrea Lara, Elena Méndez Martínez, Jorge Mendoza, Íñigo Rubio Baines, Carmen Sala Trull, Pablo Montero López. **Medicina Preventiva y Salud Pública:** Alfredo Gea, Alejandro Montero. **Hospital Universitario Dr. Peset Aleixandre:** Rocío Armero Ibañez, Juan Vicente Llau Pitarch, Fernando Rauer Alcóver, Cristina Álvarez Herreros, Cynthia Sánchez Martín, Lucía López Ocaíz Omos, Marta Navas Moruno. **Complejo Hospitalario Universitario de Cáceres:** Fernando García Montoto. MF. Mirón Rodríguez, Laura Fuentes Coco, Cristina Hernández Gamito, Antonio Barba Orejudo, Luis Gerardo Smith Vielma, Yasmina González Marín, Francisco de Borja Amador Penco, Marta Donoso Domínguez, Silvia Esquivel Ramírez. **Hospital Clínico Universitario de Valencia:** José Antonio Carbonell, Berta Monleón López, Sara Martínez-Castro, Gerardo Aguilar. **Hospital Universitario a Coruña:** María Gestal, Pablo Casas, Angel Outeiro Rosato, Andrea Naveiro Pan, María Alonso Portela, Adrián García Romar, Eva Mosquera Rodríguez, Diego Ruanova Seijo, Pablo Rama Maceiras. **Complejo Universitario de Ferrol:** Francisco Castro-Ceoane, Esther Moreno López. **Hospital Clínico Universitario Lozano Blesa:** Sergio Gil, Julia Guillén Antón, Patricia García-Consuegra Tirado, Aurora Callau Calvo, Laura Forés Lisbona, María Carbonell Romero, Belén Albericio Gil, Laura Pradal Jame, María Soria Lozano, Diego Loscos López, Andrea Patiño Abarca. **Universal Doctors:** Jordi Serrano. **UBIKARE:** Javier Pérez-Asenjo, Ángel Díez-Domínguez, Ion Zubizarreta, Jon Ramos, Iosu Fernández. **Hospital Universitario La Paz:** Emilio Maseda,
Alejandro Suárez de la Rica, Javier Veganzones, Itziar Insausti, Javier Sagra, Sofía Díaz Carrasco, Ana Montero Feijoo, Julio Yagüe. **Hospital Universitario Gregorio Marañón**: Ignacio Garutti. **Hospital San Joan Despí Moises Broggi**: Eva Bassas Parga, Carmen Deiros Garcia, Elisenda Pujol Rosa, Ana Tejedor Navarro, Roser Font Gabernet, Maria José Bernat, Meritxell Serra Valls, Cristina Cobaleda Garcia-Bernalt, Jesus Fernanz Anton, Adriana Aponte Sierra, Lucia Gil Gomez, Olaia Guenaga Vaqueiro, Susana Hernandez Marin, Laura Pardo Pinzon, Sira Garcia Aranda, Carlos Briones Orejuela, Edgar Cortes Sánchez, Alejandro Romero Fernández, Esther Fernández SanJosé, Patricia Iglesias Garsabal, Guillermo Isidro Lopez, Ana Vicol, Sara Espejo Malagon, María Sanabra Loewe, Laura Grau Torradeflo, Lourdes Blanco Alcaide, Gloria Buenaventura Sanclemente, Pere Serra Pujol, Gustavo Cuadros Mendoza, Miroslawa Konarska, Fedra Bachs Almenara, Agnieszka Golska, Aleix Carmona Blesa, Arantxa Mas Serra. **Hospital Universitario Infanta Leonor**: Javier Ripolles Melchor, Ana Nieto Moreno, Káteri Chao Novo, Sandra Gadín López, Elena Nieto Moreno, Bérénice Gutiérrez Tonal, Elena Lucena de Pablo, Barbara Algar Yañez, Beatriz Vázquez Rivero, Beatriz Nozal Mateo, Marina de Retes, Norma Aracil Escoda, Cristina Gallardo Mayo, Rosa Sanz González, Alicia Ruiz Escobar, María Laura Pelegrina López, Marina Valenzuela Peña, David Stolle Dueñas, Ane Abad Motos, Alfredo Abad-Gurumeta, Ana Tirado Errazquin, Elena Sáez Ruiz, Nerea Gómez Pérez, Francisco de Borja Bau González. **Hospital sanitas CIMA**: Cesar Morcillo Serra, Jessica Souto Higuera. **Hospital Universitario y Politécnico La Fé**: Rosario Vicente, Raquel Ferrandis, Silvia Polo Martín, Azucena Pajares Moncho, Ignacio Moreno Puigdollers, Juan Pérez Artacho Cortés, Ana Moret Calvo, Ana Pi Peña, María Catalán Fernández. **Complexo hospitalario Universitario de Pontevedra**: Marina Varela, Pilar Díaz Parada, Raquel Rey Carlín, Sarra Barreiro Aragunde. **Hospital Arnau de Vilanova**: María Isabel Forés Chiva. **Hospital General de Alicante**: A. Javier Agulló. **Hospital Universitario Infanta Sofía**: Antonio Pérez Ferrer. **Hospital Universitario San Juan de Alicante**: María Galiana. **Hospital Nuestra Señora de Meritxell SAAS**: Antoni Margarit, Válerie Mourre del Rio, Eva Heras Muxella, Anna Vidal.

**Ethics declarations**

**Conflicts of interest**

None of the authors has any conflicts of interest to declare.

**References**

1. WHO. Clinical management of COVID-19. [https://www.who.int/publications/i/item/clinical-management-of-covid-19](https://www.who.int/publications/i/item/clinical-management-of-covid-19). Accessed 20 August 2020.

2. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020;215:108448.

3. Hodgens A, Sharman T. Corticosteroids. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 14, 2020.

4. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report [published online ahead of print, 2020 Jul 17]. N Engl J Med.
5. Centers for Disease Control Prevention. Clinical Care Guidance for Healthcare Professionals about Coronavirus (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care.html. Accessed 20 August 2020

6. Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276.

7. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615-625.

8. Fadel R, Morrison AR, Vahia A, et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 [published online ahead of print, 2020 May 19]. Clin Infect Dis. 2020;ciaa601.

9. Li H, Chen C, Hu F, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020;34(6):1503-1511.

10. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.

11. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.

12. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475.

13. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854-887.

14. Johnson RM, Vinetz JM. Dexamethasone in the management of covid-19. BMJ. 2020;370:m2648.

15. Tang C, Wang Y, Lv H, Guan Z, Gu J. Caution against corticosteroid-based COVID-19 treatment. Lancet. 2020;395(10239):1759-1760.

16. Fang X, Mei Q, Yang T, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect. 2020;81(1):147-178.

17. Jung J, Oh DK, Ahn JH, et al. Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect. 2020;81(2):e79-e81.

18. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020;133(9):1039-1043.

19. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416-420.

20. Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671-1684.

21. Theoharides TC, Conti P. Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents. 2020 Jun 4;34(3).
22. Nicastri E, Petrosillo N, Ascoli Bartoli T, et al. National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020;12(1):8543.

23. Xu X, Ong YK, Wang Y. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Mil Med Res. 2020;7(1):22.

24. Meduri GU, Siemieniuk RAC, Ness RA, Seyler SJ. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care. 2018;6:53.

Figures
Figure 1

Flow chart of study participants. ICU= Intensive Care Unit.
Figure 2

Kaplan-Meier estimates of mortality according to early use of corticosteroids during the first 48h of ICU stay. The upper graphs are crude estimates. The lower graphs are inverse probability weighted (IPW) estimates (N=455).

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- SeeAdditionalFiles.docx
- AdditionalFile.docx
- TableS1corticosteroidsuse.docx
- TableS2Sensitivityanalyses.docx